AL amyloidosis is a rare and serious disease caused by abnormal plasma cells in the bone marrow that produce misfolded amyloid proteins. These proteins build up in vital organs, such as the heart, kidneys, and liver, leading to progressive, multi-organ damage. It is also associated with high mortality rates. DARZALEX FASPRO, developed by Johnson & Johnson, is the first and only approved treatment for patients with newly diagnosed AL amyloidosis. However, there are no FDA-approved therapies for relapsed/refractory AL amyloidosis patients.
The company we are profiling today is also developing a cell therapy for AL Amyloidosis - Immix Biopharma Inc. (IMMX).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com